The antiemetics and antinauseants market size has grown steadily in recent years. It will grow from $7.75 billion in 2023 to $8.09 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth observed in the historical period can be attributed to factors such as historical branding and market competition, prevailing treatment preferences in the past, economic conditions, historical global health events, as well as advancements and research in the medical field.
The antiemetics and antinauseants market size is expected to see steady growth in the next few years. It will grow to $9.46 billion in 2028 at a compound annual growth rate (CAGR) of 4.0%. The anticipated growth in the forecast period can be ascribed to initiatives in research and development, economic factors, market competition, and industry trends. Additionally, changing disease patterns, healthcare policies, and regulations are expected to contribute to this growth. Major trends anticipated during the forecast period include an enhanced focus on patient experience, evolving healthcare policies, a consumer preference for non-invasive treatments, a heightened prevalence of chemotherapy and pregnancy-related nausea, and the emergence of targeted therapies.
The growth of the antiemetics and antinauseants market is propelled by the increasing prevalence of cancer. Chemotherapy, a widely recommended cancer treatment, often leads to chemotherapy-induced nausea and vomiting (CINV) as side effects. Antiemetics play a crucial role in preventing CINV in a significant percentage of patients, approximately 60%-70%. Global cancer incidence, as reported by the World Health Organization (WHO), has reached 18.1 million new cases and 9.6 million deaths. In the United States alone, about 650,000 cancer patients undergo chemotherapy in outpatient oncology clinics annually. The demand for antiemetics and antinauseants, including drugs such as Dolasetron (Anzemet) and Ranitidine (Zantac), is expected to rise in tandem with the increased incidence of cancer, driving market revenue.
The growth of the antiemetics and antinauseants market is further fueled by the rising prevalence of tuberculosis. Tuberculosis (TB), an infectious bacterial disease primarily affecting the lungs, necessitates the use of antiemetics and antinauseants to manage nausea and vomiting induced by anti-tuberculosis medications. The Global Tuberculosis Report from the World Health Organization indicates a global TB incidence of 10.6 million cases in 2021, representing a 4.5% increase from the previous year. With the majority of cases reported in Southeast Asia and Africa, the heightened prevalence of tuberculosis is expected to contribute to the expansion of the antiemetics and antinauseants market.
A hindrance to the market's growth is the lack of awareness among practitioners regarding the variety of available antiemetic and antinauseant drugs. Despite the existence of a diverse range of drugs, practitioners often prescribe similar medications for patients with different nausea conditions. This limited prescription variety leads to lower demand for alternative drugs, restricting overall market growth. Initiatives such as the American Society of Clinical Oncology's 'Choosing Wisely' campaign aim to prevent the overuse of similar antiemetic drugs for various ailments.
Manufacturers in the antiemetics and antinauseants market are leveraging nanotechnology to enhance drug effectiveness through targeted delivery systems. Nanomedicine and Nano delivery systems involve the use of nanoparticles to optimize drug action. Merck & Co., for example, utilized nanotechnology in the creation of Aprepitant (brand name Emend), the first FDA-approved drug for preventing acute chemotherapy-induced nausea and vomiting (CINV).
Government agencies such as the US Food and Drug Administration (FDA) regulate the antiemetics and antinauseants market. In the USA, specific regulations outlined in title 21 of the FDA's Department of Health and Human Services govern the conditions that antiemetic and antinauseant drugs must fulfill to remain in the market, covering definitions, regulations, and labeling requirements.
Major companies in the antiemetic and antinauseant market are focused on product innovation, introducing solutions such as transdermal delivery systems (TDS) to meet customer needs. Transdermal delivery systems facilitate controlled medication release through the skin for systemic absorption. For instance, Starton Therapeutics Inc., a US-based biotechnology company, received FDA approval in April 2021 for STAR-OLZ transdermal delivery system (TDS) to treat chemotherapy-induced nausea and vomiting (CINV). This multi-day olanzapine transdermal delivery system demonstrated effectiveness in managing nausea, surpassing other standard-of-care therapies according to independent double-blind trials.
Major companies operating in the antiemetics and antinauseants market report are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Cipla Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Kyowa Hakko Kirin Pharma Co. Ltd., Daiichi Sankyo Company, Braun GmbH, Eisai Co. Ltd., Sun Pharmaceuticals Industries Ltd., Dr. Reddy's Laboratories, Hikma Pharmaceuticals PLC, IPCA Laboratories Ltd., Eagle Pharmaceuticals Inc., Cadila Pharmaceuticals Ltd., Bristol Laboratories Ltd., Tesaro Inc., SRS Pharmaceuticals Pvt. Ltd., Acacia Pharma Ltd., Algen Healthcare Ltd., Mirabilia Sciences Pvt. Ltd., Helsinn Healthcare SA. North America was the largest region in the antiemetics and antinauseants market in 2023. The Middle East is expected to be the fastest-growing region in the global antiemetics and antinauseants market share. The regions covered in the antiemetics and antinauseants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The primary categories of drugs within the realm of antiemetics and antinauseants encompass dopamine antagonists, NK1 receptor antagonists, antihistamines (H1 histamine receptor antagonists), cannabinoids, benzodiazepines, anticholinergics, steroids, 5-HT3 receptor antagonists, and others. Dopamine antagonists, also known as anti-dopaminergics or dopamine receptor antagonists, function by blocking dopamine receptors and find applications in chemotherapy, motion sickness, gastroenteritis, general anesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and various other contexts. These medications are utilized in diverse healthcare settings, including hospitals, medical centers, clinics, and research institutes.
The antiemetics and antinauseants market research report are one of a series of new reports that provides antiemetics and antinauseants market statistics, including antiemetics and antinauseants industry global market size, regional shares, competitors with antiemetics and antinauseants market share, detailed antiemetics and antinauseants market segments, market trends and opportunities, and any further data you may need to thrive in the antiemetics and antinauseants industry. This antiemetics and antinauseants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The countries covered in the antiemetics and antinauseants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The antiemetics and antinauseants market consists of sales of dopamine, serotonin, neurokinin, histamine, and acetylcholine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The antiemetics and antinauseants market size is expected to see steady growth in the next few years. It will grow to $9.46 billion in 2028 at a compound annual growth rate (CAGR) of 4.0%. The anticipated growth in the forecast period can be ascribed to initiatives in research and development, economic factors, market competition, and industry trends. Additionally, changing disease patterns, healthcare policies, and regulations are expected to contribute to this growth. Major trends anticipated during the forecast period include an enhanced focus on patient experience, evolving healthcare policies, a consumer preference for non-invasive treatments, a heightened prevalence of chemotherapy and pregnancy-related nausea, and the emergence of targeted therapies.
The growth of the antiemetics and antinauseants market is propelled by the increasing prevalence of cancer. Chemotherapy, a widely recommended cancer treatment, often leads to chemotherapy-induced nausea and vomiting (CINV) as side effects. Antiemetics play a crucial role in preventing CINV in a significant percentage of patients, approximately 60%-70%. Global cancer incidence, as reported by the World Health Organization (WHO), has reached 18.1 million new cases and 9.6 million deaths. In the United States alone, about 650,000 cancer patients undergo chemotherapy in outpatient oncology clinics annually. The demand for antiemetics and antinauseants, including drugs such as Dolasetron (Anzemet) and Ranitidine (Zantac), is expected to rise in tandem with the increased incidence of cancer, driving market revenue.
The growth of the antiemetics and antinauseants market is further fueled by the rising prevalence of tuberculosis. Tuberculosis (TB), an infectious bacterial disease primarily affecting the lungs, necessitates the use of antiemetics and antinauseants to manage nausea and vomiting induced by anti-tuberculosis medications. The Global Tuberculosis Report from the World Health Organization indicates a global TB incidence of 10.6 million cases in 2021, representing a 4.5% increase from the previous year. With the majority of cases reported in Southeast Asia and Africa, the heightened prevalence of tuberculosis is expected to contribute to the expansion of the antiemetics and antinauseants market.
A hindrance to the market's growth is the lack of awareness among practitioners regarding the variety of available antiemetic and antinauseant drugs. Despite the existence of a diverse range of drugs, practitioners often prescribe similar medications for patients with different nausea conditions. This limited prescription variety leads to lower demand for alternative drugs, restricting overall market growth. Initiatives such as the American Society of Clinical Oncology's 'Choosing Wisely' campaign aim to prevent the overuse of similar antiemetic drugs for various ailments.
Manufacturers in the antiemetics and antinauseants market are leveraging nanotechnology to enhance drug effectiveness through targeted delivery systems. Nanomedicine and Nano delivery systems involve the use of nanoparticles to optimize drug action. Merck & Co., for example, utilized nanotechnology in the creation of Aprepitant (brand name Emend), the first FDA-approved drug for preventing acute chemotherapy-induced nausea and vomiting (CINV).
Government agencies such as the US Food and Drug Administration (FDA) regulate the antiemetics and antinauseants market. In the USA, specific regulations outlined in title 21 of the FDA's Department of Health and Human Services govern the conditions that antiemetic and antinauseant drugs must fulfill to remain in the market, covering definitions, regulations, and labeling requirements.
Major companies in the antiemetic and antinauseant market are focused on product innovation, introducing solutions such as transdermal delivery systems (TDS) to meet customer needs. Transdermal delivery systems facilitate controlled medication release through the skin for systemic absorption. For instance, Starton Therapeutics Inc., a US-based biotechnology company, received FDA approval in April 2021 for STAR-OLZ transdermal delivery system (TDS) to treat chemotherapy-induced nausea and vomiting (CINV). This multi-day olanzapine transdermal delivery system demonstrated effectiveness in managing nausea, surpassing other standard-of-care therapies according to independent double-blind trials.
Major companies operating in the antiemetics and antinauseants market report are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Cipla Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Kyowa Hakko Kirin Pharma Co. Ltd., Daiichi Sankyo Company, Braun GmbH, Eisai Co. Ltd., Sun Pharmaceuticals Industries Ltd., Dr. Reddy's Laboratories, Hikma Pharmaceuticals PLC, IPCA Laboratories Ltd., Eagle Pharmaceuticals Inc., Cadila Pharmaceuticals Ltd., Bristol Laboratories Ltd., Tesaro Inc., SRS Pharmaceuticals Pvt. Ltd., Acacia Pharma Ltd., Algen Healthcare Ltd., Mirabilia Sciences Pvt. Ltd., Helsinn Healthcare SA. North America was the largest region in the antiemetics and antinauseants market in 2023. The Middle East is expected to be the fastest-growing region in the global antiemetics and antinauseants market share. The regions covered in the antiemetics and antinauseants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The primary categories of drugs within the realm of antiemetics and antinauseants encompass dopamine antagonists, NK1 receptor antagonists, antihistamines (H1 histamine receptor antagonists), cannabinoids, benzodiazepines, anticholinergics, steroids, 5-HT3 receptor antagonists, and others. Dopamine antagonists, also known as anti-dopaminergics or dopamine receptor antagonists, function by blocking dopamine receptors and find applications in chemotherapy, motion sickness, gastroenteritis, general anesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and various other contexts. These medications are utilized in diverse healthcare settings, including hospitals, medical centers, clinics, and research institutes.
The antiemetics and antinauseants market research report are one of a series of new reports that provides antiemetics and antinauseants market statistics, including antiemetics and antinauseants industry global market size, regional shares, competitors with antiemetics and antinauseants market share, detailed antiemetics and antinauseants market segments, market trends and opportunities, and any further data you may need to thrive in the antiemetics and antinauseants industry. This antiemetics and antinauseants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The countries covered in the antiemetics and antinauseants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The antiemetics and antinauseants market consists of sales of dopamine, serotonin, neurokinin, histamine, and acetylcholine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Antiemetics and Antinauseants Market Characteristics3. Antiemetics and Antinauseants Market Trends and Strategies32. Global Antiemetics and Antinauseants Market Competitive Benchmarking33. Global Antiemetics and Antinauseants Market Competitive Dashboard34. Key Mergers and Acquisitions in the Antiemetics and Antinauseants Market
4. Antiemetics and Antinauseants Market - Macro Economic Scenario
5. Global Antiemetics and Antinauseants Market Size and Growth
6. Antiemetics and Antinauseants Market Segmentation
7. Antiemetics and Antinauseants Market Regional and Country Analysis
8. Asia-Pacific Antiemetics and Antinauseants Market
9. China Antiemetics and Antinauseants Market
10. India Antiemetics and Antinauseants Market
11. Japan Antiemetics and Antinauseants Market
12. Australia Antiemetics and Antinauseants Market
13. Indonesia Antiemetics and Antinauseants Market
14. South Korea Antiemetics and Antinauseants Market
15. Western Europe Antiemetics and Antinauseants Market
16. UK Antiemetics and Antinauseants Market
17. Germany Antiemetics and Antinauseants Market
18. France Antiemetics and Antinauseants Market
19. Italy Antiemetics and Antinauseants Market
20. Spain Antiemetics and Antinauseants Market
21. Eastern Europe Antiemetics and Antinauseants Market
22. Russia Antiemetics and Antinauseants Market
23. North America Antiemetics and Antinauseants Market
24. USA Antiemetics and Antinauseants Market
25. Canada Antiemetics and Antinauseants Market
26. South America Antiemetics and Antinauseants Market
27. Brazil Antiemetics and Antinauseants Market
28. Middle East Antiemetics and Antinauseants Market
29. Africa Antiemetics and Antinauseants Market
30. Antiemetics and Antinauseants Market Competitive Landscape and Company Profiles
31. Antiemetics and Antinauseants Market Other Major and Innovative Companies
35. Antiemetics and Antinauseants Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Antiemetics and Antinauseants Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on antiemetics and antinauseants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for antiemetics and antinauseants? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Drug: Dopamine antagonists; NK1 receptor antagonist; Antihistamines (H1 histamine receptor antagonists); Cannabinoids; Benzodiazepines; Anticholinergics; Steroids; 5-HT3 receptor antagonists; Other Drug Types
2) By Application: Chemotherapy; Motion sickness; Gastroenteritis; General anesthetics; Opioid analgesics; Dizziness; Pregnancy; Food poisoning; Emotional stress; Other Application Types
3) By End-users: Hospital; Medical Center; Clinic; Research Institutes
Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Merck & Co. Inc.; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Bayer AG
- Novartis AG
- Sanofi SA
- AstraZeneca plc
- Abbott Laboratories
- GlaxoSmithKline plc
- Cipla Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Baxter International Inc.
- Teva Pharmaceutical Industries Ltd.
- Astellas Pharma Inc.
- Kyowa Hakko Kirin Pharma Co. Ltd.
- Daiichi Sankyo Company
- Braun GmbH
- Eisai Co. Ltd.
- Sun Pharmaceuticals Industries Ltd.
- Dr. Reddy's Laboratories
- Hikma Pharmaceuticals plc
- IPCA Laboratories Ltd.
- Eagle Pharmaceuticals Inc.
- Cadila Pharmaceuticals Ltd.
- Bristol Laboratories Ltd.
- Tesaro Inc.
- SRS Pharmaceuticals Pvt. Ltd.
- Acacia Pharma Ltd.
- Algen Healthcare Ltd.
- Mirabilia Sciences Pvt. Ltd.
- Helsinn Healthcare SA
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 8.09 Billion |
| Forecasted Market Value ( USD | $ 9.46 Billion |
| Compound Annual Growth Rate | 4.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 32 |
